UnitedHealth Group (UNH) Stock Slides as Market Rises: Facts to Know Before You Trade

UnitedHealth Group (UNH) closed the most recent trading day at $300.58, moving -1.16% from the previous trading session. This change lagged the S&P 500's daily gain of 0.14%. Meanwhile, the Dow gained 0.2%, and the Nasdaq, a tech-heavy index, added 0.27%. Heading into today, shares of the largest U.S. health insurer had lost 3.01% over the past month, lagging the Medical sector's loss of 1.34% and the S&P 500's gain of 3.97%.The upcoming earnings release of UnitedHealth Group will be of great interest to investors. The company's earnings report is expected on July 29, 2025. The company is forecasted to report an EPS of $5.08, showcasing a 25.29% downward movement from the corresponding quarter of the prior year. Meanwhile, the latest consensus estimate predicts the revenue to be $111.86 billion, indicating a 13.16% increase compared to the same quarter of the previous year. For the full year, the Zacks Consensus Estimates are projecting earnings of $21.85 per share and revenue of $449.46 billion, which would represent changes of -21.01% and +12.29%, respectively, from the prior year. Additionally, investors should keep an eye on any recent revisions to analyst forecasts for UnitedHealth Group. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook. Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model. The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 2.08% decrease. UnitedHealth Group presently features a Zacks Rank of #5 (Strong Sell). In the context of valuation, UnitedHealth Group is at present trading with a Forward P/E ratio of 13.92. This represents a premium compared to its industry average Forward P/E of 12.94. Meanwhile, UNH's PEG ratio is currently 1.46. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. The average PEG ratio for the Medical - HMOs industry stood at 0.89 at the close of the market yesterday. The Medical - HMOs industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 215, placing it within the bottom 13% of over 250 industries. The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions. Should You Invest in UnitedHealth Group Incorporated (UNH)?Before you invest in UnitedHealth Group Incorporated (UNH), want to know the best stocks to buy for the next 30 days? Check out Zacks Investment Research for our free report on the 7 best stocks to buy.Zacks Investment Research has been committed to providing investors with tools and independent research since 1978. For more than a quarter century, the Zacks Rank stock-rating system has more than doubled the S&P 500 with an average gain of +24.08% per year. (These returns cover a period from January 1, 1988 through May 6, 2024.)Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report UnitedHealth Group Incorporated (UNH): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks